Bibliography
- Phillips KA , MarshallDA, HaasJS et al.: Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.Cancer115(22) , 5166–5174 (2009).
- Welsh SJ , PowisG: Toward personalized therapy for cancer. In: Current Clinical Oncology: Targeted Cancer Therapy. Kurzrock R, Markman M (Eds). Humana Press, Totowa, NJ, USA (2008).
- Slamon DJ , ClarkGM, WongSG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science235(4785) , 177–182 (1987).
- Herceptin (trastuzumab) prescribing information. Revised October 2010, Genentech, Inc., CA, USA (2010).
- Slamon DJ , Leyland-JonesB, ShakS et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N. Engl. J. Med.344(11) , 783–792 (2001).
- Davies H , BignellGR, CoxC et al.: Mutations of the BRAF gene in human cancer.Nature417(6892) , 949–954 (2002).
- Kumar R , AngeliniS, HemminkiK: Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.Oncogene22(58) , 9217–9224 (2003).
- Mok TS , WuYL, ThongprasertS et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N. Engl. J. Med.361(10) , 947–957 (2009).
- Heinrich MC , MakiRG, CorlessCL et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J. Clin. Oncol.26(33) , 5352–5359 (2008).
- Hodi FS , FriedlanderP, CorlessCL et al.: Major response to imatinib mesylate in KIT-mutated melanoma.J. Clin. Oncol.26(12) , 2046–2051 (2008).
- Lutzky J , BauerJ, BastianBC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.Pigment Cell Melanoma Res.21(4) , 492–493 (2008).
- De Roock W , ClaesB, BernasconiD et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol.11(8) , 753–762 (2010).
- Douillard JY , SienaS, CassidyJ et al.: Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J. Clin. Oncol.28(31) , 4697–4705 (2010).
- Peeters M , PriceTJ, CervantesA et al.: Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.J. Clin. Oncol.28(31) , 4706–4713 (2010).
- Mardis ER : Next-generation DNA sequencing methods.Annu. Rev. Genomics Hum. Genet.9 , 387–402 (2008).
▪ Website
- RG7204 Phase III study shows significant survival benefit in patients with metastatic melanoma www.news-medical.net/news/20110119/RG7204-Phase-III-study-shows-significant-survival-benefit-in-patients-with-metastatic-melanoma.aspx (Accessed 19February2011)